gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PHATHealthcarePharmaceuticals

Phathom Pharmaceuticals, Inc. Common Stock (PHAT)

$5.68−1.05%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$5.92▼ 56.92% in range
Nov 3, 2025Low $5.74 · High $18.08Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Phathom Pharmaceuticals closed at $5.68 on Nov 4, down 1.05%, within 0.0% of its 52-week closing low. Volume of 1.5M shares was 0.84× its 20-day average (close to normal).

Split-adjusted performance: -16.2% over one month, -55.2% over six months, -58.6% over one year.

In the quarter ended Sep 30, 2026, revenue was $84.72M, up 71.1% from a year earlier, with a net margin of -16.4%.

Short interest was 9.8M shares at the Oct 15 settlement, down 3.2% from the prior report (17.5% of float, 6.9 days to cover).

Market cap$461.7M81.3M shares
Revenue · quarter$84.7M+71.1% YoY
Diluted EPS$-0.16—
P/E · TTM—P/S 1.7×
Net margin-16.4%Gross 78.3%
Dividend yieldNone
52-week range5.68 – 18.08−68.6% from high
Volume1.5M0.84× 20-day avg
Volatility · 60d72.0%Annualised
Short % of float17.5%6.9 days to cover
Net cash$17.6MCash $184.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.6%1M −16.2%3M −32.3%6M −55.2%YTD −65.8%1Y −58.6%3Y −36.7%5Y −77.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum21
Revenue growth83
Net margin60
Value (low P/E)—
Size59

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.8M−3.2% vs prior
Days to cover6.9Settled Oct 15
% of float17.5%
Short vol. 10d42.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PHATPhathom Pharmaceuticals$5.68−1.05%−55.2%+71.1%−16.4%—$461.7M
GYREGyre Therapeutics$4.440.00%−44.8%−2.1%−40.1%—$470.8MCompare
AQSTAquestive Therapeutics$3.80−2.06%−10.2%+38.1%−165.5%—$476.9MCompare
RLMDRelmada Therapeutics$4.17−2.34%−46.9%———$444.8MCompare
CRMDCorMedix$5.66+1.80%−29.7%+156.5%25.5%2.4$441.2MCompare
INDPIndaptus Therapeutics$3.30+1.85%+61.0%———$439.7MCompare
ARVNArvinas$7.42+4.65%−27.7%+1014.7%67.8%52.2$485.2MCompare
TLRYTilray Brands$2.96+11.70%−48.6%+22.7%−16.8%—$437.5MCompare
MNPRMonopar Therapeutics$72.81+4.18%+14.0%———$488.7MCompare

News about Phathom Pharmaceuticals

All news →
Phathom Pharmaceuticals to Participate in November Investor ConferencesGlobeNewswire Inc. · 18h agoNeutralPhathom Pharmaceuticals Provides Update on FDA LitigationGlobeNewswire Inc. · Oct 26, 2026▼ NegativePhathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAGlobeNewswire Inc. · Oct 23, 2026▼ NegativePhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 1, 2026▲ PositivePhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingGlobeNewswire Inc. · May 1, 2026▲ Positive

Quick answers

What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
What is PHAT's market cap?
$461.74M, based on the Nov 4 close of $5.68.
Does Phathom Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PHAT is sold short?
9.8M shares, 17.5% of float, as of Oct 15, 2026.
What sector is PHAT in?
Healthcare, in the Pharmaceuticals industry.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

HQ: Florham Park, NJ371 employeesListed Oct 25, 2019phathompharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology